Navigation Links
Pharmacyclics Receives Non-Approvable Letter from the FDA for Xcytrin for the Treatment of Lung Cancer Brain Metastases
Date:12/21/2007

is (programmed cell death). Its multifunctional mode of action, including its magnetic resonance imaging detectability and its non-overlapping toxicity, make Xcytrin an appealing agent to use in combination with standard chemotherapy regimens, potentially across a broad range of cancers.

In addition to Xcytrin, the company's other product candidates include a histone deacetylase (HDAC) inhibitor in a Phase 1/2 trial, and a Factor VIIa inhibitor and a Bruton's tyrosine kinase (BTK) inhibitor in pre-clinical testing for cancer and autoimmune diseases.

About Pharmacyclics

Pharmacyclics is a pharmaceutical company developing innovative products to treat cancer and other serious diseases. The company is leveraging its small-molecule drug development expertise to build a pipeline in oncology and other diseases based on a wide range of targets, pathways and mechanisms. Its lead product, Xcytrin, has completed Phase 3 clinical trials and several ongoing Phase 1 and Phase 2 clinical trials are evaluating Xcytrin, either as a single agent or in combination with chemotherapy and/or radiation in multiple cancer types. More information about the company, its technology, and products can be found at http://www.pharmacyclics.com. Pharmacyclics(R), Xcytrin(R) and the "pentadentate" logo(R) are registered trademarks of Pharmacyclics, Inc.

Taxotere(R) is a registered trademark of Sanofi-Aventis.

Alimta(R) is a registered trademark of Eli Lilly and Company.

NOTE: Other than statements of historical fact, the statements made in this press release about the initiation of and enrollment and future plans for our clinical trials, progress of and reports of results from preclinical and clinical studies, clinical development plans and product development and corporate partnering activities are forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995.
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Lake Elsinore Family Caregiver Receives Free Power Wheelchair From The SCOOTER Store
2. DaVita Receives Civil Complaint
3. Ranbaxy Receives Tentative Approval to Manufacture and Market Galantamine Tablets on an Exclusive Basis
4. Watson Receives First FDA Approval for Manufacturing Product at Its Goa, India Facility
5. Edwards Lifesciences Receives CE Mark for Edwards SAPIEN Transcatheter Heart Valve
6. PainCare Receives $14.4 Million in Cash From Completed Sale of South Florida Ambulatory Surgery Centers
7. UT Southwesterns obesity research receives $22 million NIH Roadmap grant
8. Temple Emergency Medicine receives $1.8M to find best MRSA treatment
9. Prime Therapeutics Receives TIPPS Certification
10. Bioniche Receives $2 Million Government Grant For Market Development Related to its E. coli O157:H7 Cattle Vaccine
11. UCLA receives $22.5 million to explore the fundamental biology of mental disorders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... TX (PRWEB) October 25, 2014 ... Chinese Molecular Diagnostics Industry, 2009-2019 is a ... and Chinese Molecular Diagnostics industry. The report ... Diagnostics including its classification, application and manufacturing ... China’s top manufacturers of Molecular Diagnostics listing ...
(Date:10/25/2014)... 25, 2014 Limbkeepers® announced today that ... Innovations with Ed Begley Jr, airing 1st QTR 2015 ... In this episode, Innovations will focus on Limbkeepers® non ... fragile, thinning skin on arms, hands, and legs from ... these versatile products, which help reduce injuries, allow for ...
(Date:10/25/2014)... Oct. 23, 2014 (HealthDay News) -- A large influx ... Africa is to avoid tens of thousands of deaths ... University researchers predict. Using a specially designed ... of the outbreak in just one densely populated county ... capital city of Monrovia. The researchers said that ...
(Date:10/22/2014)... TX (PRWEB) October 22, 2014 On Saturday, ... present its fourth annual family health and fitness fair ¡Vive ... family physical activity and good nutrition for better health and ... event, which is free and open to the public, will ... in Brownsville, from 9:00 am to 1:00 pm. , ...
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. ... three Ebola cases in Dallas. But, mental health specialists say ... President Barack Obama on Friday appointed an Ebola "czar" ... infected two Dallas nurses who cared for a Liberian man ... Hospital. But the U.S. cases are miniscule in the ...
Breaking Medicine News(10 mins):Health News:Global and China Molecular Diagnostics Industry Analysis to 2019 is Now Available at RnRMarketResearch.com 2Health News:Global and China Molecular Diagnostics Industry Analysis to 2019 is Now Available at RnRMarketResearch.com 3Health News:Global and China Molecular Diagnostics Industry Analysis to 2019 is Now Available at RnRMarketResearch.com 4Health News:Upcoming Episode of Innovations with Ed Begley, Jr. to Feature Limbkeepers® 2Health News:Experts Predict 'Catastrophic' Ebola Epidemic in West Africa if Aid Delayed 2Health News:Brownsville Community Health Center Presents Fourth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 2Health News:Brownsville Community Health Center Presents Fourth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 3Health News:Brownsville Community Health Center Presents Fourth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 4Health News:Ebola Anxiety: A Bigger Threat Now Than the Virus Itself 2Health News:Ebola Anxiety: A Bigger Threat Now Than the Virus Itself 3
... Inc. (Nasdaq:,LCAV), a leading provider of laser vision correction ... LasikPlus vision center in Des,Moines, Iowa. This marks the ... first LasikPlus vision center in the state of Iowa.,LasikPlus ... 58 markets., Similar to other LasikPlus vision centers ...
... Myriad Opportunities for Using Wireless ... and Accuracy of Patient Care, WALTHAM, Mass., Feb. ... wireless LANs (WLANs) for enterprises and,service providers, will leverage ... taking place February 24-28 in Orlando, FL, to,showcase how ...
... Deliver Clinical ... Data Faster and Improve Productivity, WALTHAM, Mass., ... intelligent wireless LANs (WLANs) for enterprises and,service providers, today ... http://www.cardiacscience.com ), the leading provider of,cardiac monitoring, defibrillation and ...
... and Increased Uptake of, CellCept Will Provide Effective ... ... WALTHAM, Mass., Feb. 25 Decision Resources, one of ... finds that the entry and uptake of high-priced branded,agents will ...
... Patients to Orchestrate Health ... Information ... provider,of next generation healthcare connectivity solutions, today announced the,first public ... HealthVault(TM), at the 2008 HIMSS,(Healthcare Information and Management Systems Society) ...
... SOUTH SAN FRANCISCO, Calif., Feb. 25 Hyperion,Therapeutics, ... been enrolled,in a Phase 2 clinical trial of ... patients with Grade III or IV hepatic,encephalopathy (HE). ... safety and efficacy of AMMONUL versus standard of ...
Cached Medicine News:Health News:LCA-Vision Announces the Opening of its 74th LasikPlus Vision Center in Des Moines, Iowa 2Health News:Colubris Demonstrates Wide-Ranging Mobility Solutions for Healthcare 2Health News:Cardiac Science Corporation Selects Colubris Networks' Wireless Solution for its Portable Electrocardiograph 2Health News:Cardiac Science Corporation Selects Colubris Networks' Wireless Solution for its Portable Electrocardiograph 3Health News:Uptake of Branded Agents Will Drive the Systemic Lupus Erythematosus Drug Market to Quadruple to $1.4 Billion in 2016 2Health News:Kryptiq and Microsoft to Showcase Unprecedented Connectivity Between Consumers and Their Doctors at HIMSS '08 2Health News:Kryptiq and Microsoft to Showcase Unprecedented Connectivity Between Consumers and Their Doctors at HIMSS '08 3Health News:Hyperion Therapeutics Announces Enrollment of First Patient in Phase 2 Clinical Trial in Patients With Hepatic Encephalopathy 2Health News:Hyperion Therapeutics Announces Enrollment of First Patient in Phase 2 Clinical Trial in Patients With Hepatic Encephalopathy 3
(Date:10/22/2014)... , Oct. 22, 2014  Paper Pak Industries, ... developed APLS ® Body Guard Bio, a ... spread of bacteria and virus while protecting service ... Guard Bio features a rugged, external nylon shell, ... create a leak-proof inner chamber that contains contaminated ...
(Date:10/22/2014)... 2014 A new report by ... type, Form, End user, Application and Geography) - Size, ... Report, Opportunities, Segmentation and Forecast, 2013 - 2020", considers ... on key trends tracked, it is anticipated that the ... by 2020, registering a CAGR of 6.2% from 2014 ...
(Date:10/22/2014)... 22, 2014  With a vision to ensure ... a Global Pharmaceutical and Biotech manufacturer selects and ... turnkey solution to protect their animal health brand.  ... Photo - http://photos.prnewswire.com/prnh/20141021/153439 ... and aggregated by the Xyntek and Antares solution ...
Breaking Medicine Technology:New, State-Of-The-Art Body Bag Minimizes The Spread Of Bacteria And Virus 2Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 2Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 3Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 4Xyntek and Antares Serialization Solution Protects Pets Too! 2
... studies support the development of DG041 as ... risk, REYKJAVIK, Iceland, June 25, 2007 /PRNewswire-FirstCall/ ... development of,DG041, the company's Phase II developmental ... results of the Phase IIa and,clinical pharmacology ...
... Significant Clinical Results for,SB-509 in Development for ... 2007 /PRNewswire-FirstCall/ -- Sangamo,BioSciences, Inc. announced today ... from its ZFP Therapeutic(TM) program at the,67th ... As disclosed in an oral presentation entitled, ...
Cached Medicine Technology:Positive Clinical Results for DG041 Lead Product Development,Highlights at deCODE R&D Event 2Positive Clinical Results for DG041 Lead Product Development,Highlights at deCODE R&D Event 3Positive Clinical Results for DG041 Lead Product Development,Highlights at deCODE R&D Event 4Positive Clinical Results for DG041 Lead Product Development,Highlights at deCODE R&D Event 5Positive Clinical Results for DG041 Lead Product Development,Highlights at deCODE R&D Event 6Sangamo BioSciences Announces Presentation of Phase 1 ZFP,Therapeutic Data at American Diabetes Association Meeting 2Sangamo BioSciences Announces Presentation of Phase 1 ZFP,Therapeutic Data at American Diabetes Association Meeting 3Sangamo BioSciences Announces Presentation of Phase 1 ZFP,Therapeutic Data at American Diabetes Association Meeting 4Sangamo BioSciences Announces Presentation of Phase 1 ZFP,Therapeutic Data at American Diabetes Association Meeting 5Sangamo BioSciences Announces Presentation of Phase 1 ZFP,Therapeutic Data at American Diabetes Association Meeting 6Sangamo BioSciences Announces Presentation of Phase 1 ZFP,Therapeutic Data at American Diabetes Association Meeting 7Sangamo BioSciences Announces Presentation of Phase 1 ZFP,Therapeutic Data at American Diabetes Association Meeting 8Sangamo BioSciences Announces Presentation of Phase 1 ZFP,Therapeutic Data at American Diabetes Association Meeting 9
...
EDM Ventricular Drainage Kit, with Drip Chamber with and without Bioglide are fabricated of radiopaque (barium impregnated) silicone tubing, and are packaged with stainless steel stylets inserted in ...
Medtronic neurosurgery external drainage and monitoring (EDM) products meet a variety of needs for CSF drainage and monitoring....
... The CODMAN EDS 3 CSF External Drainage System ... nurses and physicians. The clinicians who work every ... the CODMAN EDS 3: ease-of-use in an integrated ... valve, accurate hydrostatic leveling from a unique ...
Medicine Products: